A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching
VM Riccardi - Archives of dermatology, 1993 - jamanetwork.com
• Background and Design.—Based on potential contributions of mast cells to neurofibroma-
associated itching, pain, and tenderness, the mast cell blocker ketotifen fumarate (Zaditen,
Sandoz Pharmaceuticals Corp, Hanover, NJ) has been proposed as a treatment for these
symptoms. To test the hypothesis that ketotifen decreases neurofibroma-associated itching,
pain, and tenderness, data were accumulated from two protocols. The first was an open-
label protocol involving 25 patients with relatively severe symptoms (1170 patient-months) …
associated itching, pain, and tenderness, the mast cell blocker ketotifen fumarate (Zaditen,
Sandoz Pharmaceuticals Corp, Hanover, NJ) has been proposed as a treatment for these
symptoms. To test the hypothesis that ketotifen decreases neurofibroma-associated itching,
pain, and tenderness, data were accumulated from two protocols. The first was an open-
label protocol involving 25 patients with relatively severe symptoms (1170 patient-months) …